Guardant Health to Present 25 Liquid Biopsy Research Abstracts at ESMO 2026

By Public Technologies
  • Guardant Health will present 25 abstracts, including five rapid oral presentations, at ESMO Congress 2026, October 23-27 in Madrid.
  • FORTITUDE findings suggest FGFR2 amplification may identify patients with advanced gastric or gastroesophageal junction cancer more sensitive to bemarituzumab.
  • CROWN findings suggest genomic complexity and changes in methylation-based assays may identify patients at risk of early progression on lorlatinib.
  • NADIM II analysis linked undetectable postsurgical residual disease to favorable long-term outcomes; detectable disease identified patients at high risk of early recurrence.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610200902BIZWIRE_USPR_____20261019_BW515698) on October 20, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk